Advertisement

We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

Shutterstock/Delmas Lehman
Indiana

Some Amish people live 10 years longer than their neighbours. Scientists say it's because of a gene mutation

Amish people with this gene mutation were also significantly less likely to get diabetes.

SCIENTISTS HAVE FOUND a genetic mutation in the Amish people of the midwestern United States that appears to make them live 10 years longer than people without it, a study said this week.

The report in the journal Science Advances is the latest clue in a decade-plus search for the secrets to healthy aging in this traditional, Christian community that balks at most modern technology.

Researchers in the US and Japan are currently testing an experimental drug that aims to recreate the effect of this mutation in people, in the hopes it may protect against age-related illnesses and boost longevity.

“Not only do they live longer, they live healthier,” said lead author Douglas Vaughan, chairman of medicine at Northwestern University Feinberg School of Medicine.

It’s a desirable form of longevity.

Researchers studied 177 members of the Berne Amish community in Indiana, and found 43 who had one mutant copy of the gene, SERPINE1.

These carriers lived to 85 on average, while those without it in the Amish community tend to live to 75.

Amish people with this gene mutation were also significantly less likely to get diabetes, and they had more efficient metabolisms.

The key protein at play in the aging of cells appears to be PAI-1 (plasminogen activator inhibitor) which is influenced by SERPINE1.

PAI-1 is known to be related to aging in animals but its effect in humans has been less clear.

Northwestern University researchers have partnered with Japan’s Tohoku University to develop and test an experimental drug that would inhibit the action of PAI-1, like in Amish people with the mutant gene.

The drug has passed basic safety trials and is now being tested in phase 2 trials in Japan on how well it works on insulin sensitivity in people type 2 diabetes and obesity.

Northwestern is seeking regulatory approval to begin a US trial next year.

© – AFP 2017

Read: Kids on Amish farms are less likely to get asthma – a new study explains why >

Your Voice
Readers Comments
49
This is YOUR comments community. Stay civil, stay constructive, stay on topic. Please familiarise yourself with our comments policy here before taking part.
Leave a Comment
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.

    Leave a commentcancel

     
    JournalTv
    News in 60 seconds